A study of blood vessel reactivity in liver cirrhosis

Phase 1

• Conditions: iver cirrhosis; Liver cirrhosis; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

• Registration Number: ACTRN12613000155796
• Lead Sponsor: iver Transplant Unit, Austin Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-02-08
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

Liver cirrhosis

Absence of liver disease in healthy control group

Exclusion Criteria

Control group participants will not have evidence (clinical/laboratory) of underlying liver disease.

Use of Angiotensin Converting Enzyme inhibitor, Angiotensin Receptor Blocker or Beta blocker medications.
Cardiovascular disease
Hypertension
Pulmonary disease (other than Hepato-Pulmonary Syndrome)
Renal disease (other than Hepato-Renal Syndrome)
>20g alcohol per day in past 6 months.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome of the study will be changes in FBF (from baseline) per minute during Ang 1-7 infusion in ‘cirrhosis’ vs health as measured by FP. <br><br>FBF is measured where a strain gauge applied around the forearm is attached to a plethysmograph to record degree of stretch in the gauge. The rate of change in forearm volume gives an estimation of total forearm blood flow expressed as ml/100ml forearm volume per minute.<br>[Concentration respone curve to Ang 1-7 over a fifteen minute infusion period]